The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to ...

"FDA approves Vertex’s acute pain treatment Journavx" was originally created and published by Pharmaceutical Technology, a ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

“I think in acute pain this drug has great promise,” said Michael ... While the clinical trial showed the drug could be ...

Acute pain is short-term pain often caused by injuries ... and herbal supplements – before starting their treatment to avoid possible interactions.

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit ...

CenExel, a leading network of clinical research sites, proudly congratulates and announces its role in supporting Vertex Pharmaceuticals’ clinical studies that led to the FDA approval of JOURNAVX™ ...

The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.

The US FDA has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults.

It is indicated for the management of all forms of moderate to severe acute pain. Its approval marks a significant milestone in the treatment of acute pain, which affects 80 million Americans ...